Men who already carry the genetic profile for the most common form of baldness have roughly a 7 percent added risk of losing their hair when GLP-1 receptor activity is higher, according to research from NYU Langone Health published Thursday in the Journal of Investigative Dermatology. The researchers describe it as the first genetic evidence connecting the biology behind drugs like Ozempic, Wegovy and Zepbound to male pattern hair loss.
The distinction matters for anyone reading the headline and reaching for a prescription bottle. Researchers did not follow patients taking these medications and count how many lost hair. They compared genetic data, using the GLP1R gene as a stand-in for the drugs' biological effect, and looked for overlap with the genes found in men who have androgenetic alopecia.
